Prostate cancer: SBRT consecutive day and weekly regimens are safe

  • Necchi A & al.
  • Eur Urol
  • 9 Mar 2020

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Urethra-sparing stereotactic body radiotherapy (SBRT) shows favorable biochemical control rates and a low toxicity profile and maintains QoL regardless of overall treatment time (OTT) in patients with prostate cancer.

Why this matters

  • SBRT shows good disease control, but information on the effect of OTT in terms of biochemical RFS is limited.

Study design

  • Phase 2 study: 170 patients with prostate cancer were randomly assigned to urethra-sparing SBRT delivered either every other day (OTT, 10-12 days) or once a week (OTT, 30 days).
  • Funding: Fundació Privada Cellex; Brianlab.

Key results

  • All patients completed the treatment schedule.
  • At week 12, patients reported:
    • Satisfactory urinary QoL in both groups.
    • Mild gastrointestinal toxicity, no grade 3 events, and
    • No changes in gastrointestinal and genitourinary EORTC QLQ-PR25 scores.
  • At week 18:
    • 1 grade 3 genitourinary toxicity (obstructive symptoms) was reported (with a dose every other day).
    • GI toxicity was mild with 70% of patients in both groups.
    • Genitourinary EORTC QLQ-PR25 scores improved (median, 12 vs 8).
    • Sexual domains (activity and functioning) remained stable.
    • The EORTC QLQ-C30 global health status domain remained stable.
  • 2 biochemical failures were reported in each group.

Limitations

  • Short follow-up.